Background: Although effective antifungal agents for the treatment of candidemia have recently been introduced, the mortality rate attributed to candidemia remains high (19~49%).
INTRODUCTION
The incidence of invasive fungal infections is increasing, with infection by Candida species being the most common type of fungal infection (70~ 87%) 1 . In particular, there has been a 5-to 10-fold rise in nosocomial bloodstream infections (BSIs) caused by Candida species in the past 20 years, such that Candida BSIs are now the fourth leading cause of nosocomial BSIs in the United States 2, 3 . Candidemia is associated with significant affects overall and cause-specific mortality, excessive morbidity, and prolongation of hospital stay 4~6 . Several studies have shown that the mortality rate of nosocomial candidemia is approximately 30~ 60% among patients admitted to intensive care units (ICUs) 7~9 . In Korea, the candidemia-related incidence and mortality rates among severe burn patients are 8.6% and >40%, respectively. In another study from 2009, Han et al found that the incidence and mortality rates of candidemia in ICU patients are 0.9% and 96%, respectively 10 . Delayed diagnosis and inappropriate therapy for candidemia results in increased mortality 11 . Early recognition of candidemia is important, but this is made difficult by the lack of specific signs and symptoms in patients and diagnostic tools to detect infections. Although newer, technologically advanced methods to detect candidemia have been developed, including 1,3-β-D-glucan assays, fungal DNA identification, C. albicans germ tube antibody tests, and mannan and anti-mannan antibody detection 1 , the high cost, lack of experience among the hospital staff with these methods, and limited hospital resources prevent our hospital from these methods. Therefore, we used a Candida Score to detect candidemia infections 1, 12 . While a Candida Score is useful, it is not frequently used in the clinical setting because routine cultures for Candida species are difficult to perform. In the present study, we evaluated the risk factors for mortality in patients with candidemia and the usefulness of a Candida Score in detecting infections.
MATERIALS AND METHODS
We conducted a retrospective study at a 750-bed tertiary medical center in the Republic of Korea. During a 9-year period (March 2003 to February 2012), all hospitalized patients with a positive blood culture for Candida species were analyzed.
Patient medical records were reviewed for demographic data, age, sex, and underlying diseases such as diabetes mellitus, chronic obstructive pulmonary disease, liver cirrhosis, chronic kidney disease, end-stage renal disease (ESRD; with the patient receiving hemodialysis), congestive heart failure, solid organ transplant, malignancy, human immunodeficiency virus infection, and neutropenia at the time of candidemia. We also obtained data regarding the patients' history of surgery, number of hospital days before candidemia infection and within 30 days of admission, use of total parenteral nutrition (TPN) and steroids, prior use of broadspectrum antibiotics, prior ICU admission, use of mechanical ventilation, use of a Foley catheter and central catheter, combined bacteremia, Candida colonization, and the species identified, presumed source of Candida infection, Candida Scores, antifungal treatment (duration and agent), and outcomes. The severity of illness was based on the Acute Physiology and Chronic Health Evaluation II (APACHE II) score, presence of severe sepsis, white blood cell count, and albumin level.
Candidemia-related death was defined as the patient dying within 30 days of the initial blood samples testing positive for Candida species. The Candida Score was calculated by assigning 1 point for TPN, surgery, and multifocal Candida species colonization and 2 points for clinical severe sepsis (the variables were coded as 0 = absent and ≥1 = present).
For comparing patients who died and those who survived, continuous variables were analyzed by Student's t-test for normally distributed variables and the Mann-Whitney U test for variables that were not normally distributed. The chi-square or Fisher's exact test was used to compare categorical variables. Values are expressed as the mean (SD) (continuous variables) or as a percentage of the group from which they were derived (categorical variables). Univariate and multivariate analyses were performed with SPSS, version 17.0 (SPSS, Chicago, Illinois, USA). P values less than or equal to 0.05 were considered significant.
RESULTS

Patient demographics
During the study period, a total of 60 patients with candidemia were included for analysis. The mean (SD) age of the patients was 61.8 (18.9) years and the mean (SD) APACHE II score was 19.6 (8.8). Forty-one patients (68.3%) were men, 23 patients (38.3%) had diabetes mellitus, 10 patients (16.7%) had ESRD and were receiving hemodialysis, 25 patients (41.7%) had an underlying malignancy, and 9 patients (15.0%) had neutropenia.
At the time of hospital admission for candidemia infection, 19 patients (31.7%) had a history of surgery, 29 patients (48.3%) had been given TPN, 37 patients (61.7%) were administered broadspectrum antibiotics, 24 patients (40%) had mechanical ventilation, 48 patients (80%) had been admitted to an ICU, and 42 patients (70%) had a central catheter. Thirty-six patients (60%) had severe sepsis and 22 patients (36.7%) had combined bacteremia. Nine patients (15%) had blood cultures positive for Candida species colonization. The Candida Score was measured in all patients, and showed that 23 patients (38.3%) had 
Risk factors for mortality
The disease-related mortality rate was 61.7% (n = 37). Univariate analysis showed that the risk factors for mortality included presence of a malignancy, receiving mechanical ventilation, having a Table 4) .
DISCUSSION
In 2006, Garey et al found that the time from the onset of candidemia to the initiation of fluconazole therapy had an impact on mortality rates in patients with candidemia, with lowest mortality rates seen in patients who started therapy on day 0 (n = 14 patients [15%]), followed by patients who started therapy on day 1 (n = 9 [24%]), day 2 (n = 12 [37%]), and day ≥3 (n = 12 [41%]) 11 . Another study examining the effects of delayed treatment found that deferment of treatment for >12 hours was an independent predictor of hospital mortality rate 12 . In our study, patients who survived had started antifungal agents an average of almost 2 days earlier than those who died, but this was not a significant finding. Early detection of a candidemia infection can result in early initiation of empirical antifungal treatment. Newer diagnostic methods for detecting candidemia have been developed (e.g., 1,3-β-D-glucan assays, fungal DNA identification, C. albicans germ tube antibody, and mannan and anti-mannan antibody tests) 1 , but these methods are not yet intended for general use.
In 2006, Leon et al suggested using a Candida Score to detect candidemia and found a sensitivity rate of 81.4% and a false-positive rate of 25.9%. The cutoff value was a score of >2.5, with sepsis, multifocal Candida colonization, parenteral nutrition, and surgery contributing to the score 13 . Leon et al showed that, in patients with a Candida Score of <3 who were not receiving antifungal treatment, the rate of invasive candidiasis was <5%; therefore, invasive candidiasis was highly improbable if patients had a Candida Score of <314. In our study, while the patients had several risk factors for candidemia, the sensitivity of the Candida Score was only 38.3% (cutoff value >2.5). This may be due to the retrospective nature of the study and the fact that patients were not routinely tested for Candida colonization. Had the patients been routinely tested for Candida colonization, the sensitivity of the Candida Score may have been higher. However, a routine Candida colonization test may be difficult in a setting with limited resources. The development of an easier prediction tool for candidemia is therefore needed.
Earlier studies have shown an overall candidemia mortality rate of approximately 60% among adults 15~17 , and the mortality rate attributable to candidemia has been reported to be as high as 38% 17 . Recent studies have suggested lower overall and attributable candidemia mortality rates 4, 18 . The risk factors for death caused by candidemia are known to be a high APACHE II score, presence of other bacteremia, sepsis, comorbid conditions (like malignancy), Candida species (C. glabrata and C. krusei), and catheter insertion, as well as other factors. In our study, the disease-related mortality rate was 61.7%, which was associated with patients having combined bacteremia (but this was not found to be significant in statistical analysis) and failure to detect invasive candidiasis early which tended to delay the initiation empirical treatment with antifungal agents. Specifically, the mortality rate of patients with candidemia caused by C. glabrata (n = 3), C. krusei (n = 3), and C. catenulate (n = 1) was 100%. Only 1 patient with C. glabrata infection received fluconazole, and 2 patients with C. krusei infection received amphotericin B and caspofungin, respectively. First of all, C. glabrata and C. krusei infection were known that mortality is high and they have resistance for antifungal agents 19 . However, these patients received therapies more than 1 week after the blood culture, at which point they already had high APACHE II scores. In addition, we could not decide its appropriateness because of lack information regarding the susceptibility to antifungal agents in our center.
This study determined that the risk factors for disease-related death were having a higher APACHE II score and presence of a malignancy. Moreover, treatment with antifungal agents decreased the mortality rate. However, this study has several limitations. First, data was collected from a single center, resulting in a limited sample size that may reflect regional infection patterns. Second, patients were evaluated retrospectively, meaning that the results may have been influenced by reviewer bias. Third, routine culture testing for all patients with candidemia was not performed.
In conclusion, the Candida Score used in our study was not found to be useful because its sensitivity was not high (38.3%). The risk factors for mortality in patients with candidemia are a high APACHE II score and presence of a malignancy. Novel, easy-to-implement, and lowcost methods to rapidly identify candidemia are needed to promptly commence antifungal therapy and improve the mortality rate for patients with candidemia. Especially in a limited resource setting, clinicians should consider the possibility of candidemia in critically ill patients: in suspected cases. repeated blood culture and empirical antifungal therapy are recommended. If possible, new nonculture-based microbiological tools such as C. albicans germ tube antibody detection or PCR techniques can be used to detect infection.
